drugset / Trial / NCT02787642
A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
A phase Ib study of Olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma.
Timeline
- Start
- 2016-01
- Primary completion
- 2021-10
- Completion
- 2022-05
Publications
- Results Sargos P, Sunyach MP, Ducassou A, Llacer C, Dinart D, Michot A, Valentin T, Firmin N, Blay JY, Gillon P, Bellera C, Italiano A. Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study. Ann Oncol. 2025 May;36(5):592-600. doi: 10.1016/j.annonc.2025.01.016. Epub 2025 Jan 31.
- Vatner R, James CD, Sathiaseelan V, Bondra KM, Kalapurakal JA, Houghton PJ. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28439. doi: 10.1002/pbc.28439. Epub 2020 Aug 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 25 mg | Oral |
| Subject | Olaparib | Small molecule | 50 mg | Oral |
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 150 mg | Oral |